Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.
Fotini VogiatziDorothee WinterbergLennart LenkSwantje BuchmannGunnar CarioMartin SchrappeMatthias PeippPaulina Richter-PechanskaAndreas E KulozikJana LentesAnke K BergmannThomas ValeriusFabian-Simon FrielitzChristian KellnerDenis M SchewePublished in: Blood (2019)